What Is HRT

Hormone replacement therapy (HRT) is the medical use of exogenous hormones, primarily estrogen and progesterone, to compensate for the decline in ovarian hormone production that accompanies perimenopause and menopause. It is delivered through oral tablets, transdermal patches, topical gels, vaginal rings, or pellet implants. HRT is also referred to as menopausal hormone therapy (MHT) in clinical literature.

The menopausal transition involves a steep decline in estradiol and progesterone production as the ovaries cease follicular activity. This hormonal shift is not merely a reproductive event; it affects bone mineral density, cardiovascular function, cognitive performance, body composition, sleep quality, and mood regulation. The average woman spends roughly a third of her life in a post-menopausal hormonal state, making this transition one of the most consequential inflection points for long-term health.

From a longevity standpoint, the loss of endogenous estrogen accelerates several aging-related processes. Bone resorption outpaces bone formation, increasing fracture risk. Vascular endothelial function deteriorates, shifting cardiovascular risk profiles. Insulin sensitivity may decline. Brain regions rich in estrogen receptors, particularly the hippocampus and prefrontal cortex, lose a key trophic signal. HRT addresses whether restoring these hormone levels can slow or partially reverse these downstream effects, making it one of the most studied interventions at the intersection of women's health and aging biology.

Estrogen exerts its effects through two main nuclear receptors, estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), which are distributed across bone, brain, cardiovascular tissue, skin, and the genitourinary tract. When estradiol binds these receptors, it modulates gene transcription in ways that maintain bone turnover balance, support endothelial nitric oxide production for vascular health, regulate cholesterol metabolism through hepatic LDL receptor expression, and sustain neuronal signaling in the central nervous system. Exogenous estrogen supplied through HRT reactivates these receptor-mediated pathways.

Progesterone, or its synthetic counterparts (progestins), is included in HRT regimens for women who still have a uterus. Unopposed estrogen stimulates endometrial proliferation and significantly increases the risk of endometrial hyperplasia and cancer. Progesterone counteracts this by promoting secretory transformation and periodic shedding of the endometrial lining. Beyond uterine protection, progesterone modulates GABA-A receptors in the brain, contributing to its calming and sleep-supportive effects. Bioidentical micronized progesterone and synthetic progestins differ in their receptor binding profiles, which influences both efficacy and side effect patterns.

Delivery route matters mechanistically. Oral estrogen undergoes first-pass hepatic metabolism, which increases production of clotting factors, sex hormone binding globulin (SHBG), and triglycerides. Transdermal estrogen bypasses the liver, delivering estradiol directly to systemic circulation and largely avoiding these hepatic effects. This distinction has clinical implications: transdermal delivery is associated with a lower risk of venous thromboembolism and may be preferred in women with metabolic risk factors, obesity, or a history of clotting concerns.

The female hormonal landscape is not a single switch that turns off at menopause; it is a gradual, often erratic transition spanning years. During the reproductive years, the ovaries produce estradiol in a cyclical pattern orchestrated by follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary. Progesterone rises after ovulation, sustaining the endometrial lining and exerting systemic effects on mood, sleep, and immune modulation. As the ovarian follicle reserve diminishes during perimenopause, cycles become irregular, progesterone production drops first (due to increasing anovulatory cycles), and estrogen levels fluctuate widely before eventually declining.

This sequence matters because the hormonal deficit is not uniform. Many women experience relative estrogen dominance during perimenopause as progesterone falls while estrogen remains variable or even elevated in some cycles. This can produce symptoms like breast tenderness, heavy bleeding, irritability, and insomnia that differ substantially from the low-estrogen symptoms (hot flashes, vaginal dryness, bone loss) that characterize later menopause. HRT prescribing must account for where a woman sits on this continuum rather than treating menopause as a single hormonal event.

Adrenal-produced DHEA and its conversion to downstream androgens and estrogens become more significant after ovarian retirement. Testosterone, though primarily associated with male physiology, plays a role in female libido, energy, and muscle maintenance, and its gradual decline contributes to the symptom burden. A comprehensive HRT strategy may consider DHEA or low-dose testosterone alongside estrogen and progesterone, depending on clinical presentation and lab findings.

The symptom profile of hormonal decline is broad and often underrecognized. The most commonly discussed symptoms are vasomotor: hot flashes and night sweats, which affect roughly 75% of menopausal women and can persist for years. These result from estrogen withdrawal's effect on the hypothalamic thermoregulatory center, which narrows the thermoneutral zone and triggers inappropriate heat-dissipation responses.

Beyond vasomotor symptoms, declining estrogen contributes to urogenital atrophy (vaginal dryness, urinary urgency, recurrent urinary tract infections), joint stiffness, accelerated skin aging, and shifts in body fat distribution from a gynoid to android pattern. Cognitive symptoms include word-finding difficulty, reduced working memory, and impaired concentration, sometimes labeled "brain fog." Mood changes range from increased anxiety and irritability to frank depressive episodes, particularly during perimenopause when hormone fluctuations are most volatile. Sleep fragmentation occurs independently of night sweats in many women, implicating progesterone's GABA-ergic effects as well as circadian rhythm disruption.

These symptoms are not merely discomforts to endure. They are clinical signals of receptor-level deprivation across multiple organ systems. Tracking their onset, trajectory, and severity provides critical diagnostic information and helps clinicians evaluate whether and how HRT should be introduced.

HRT regimens fall into several categories based on hormone type, delivery method, and dosing schedule. Estrogen-only therapy is used in women who have had a hysterectomy, since endometrial protection from progesterone is unnecessary. Combined therapy pairs estrogen with a progestogen, either continuously (no withdrawal bleed) or cyclically (with a scheduled bleed). The choice between these depends on whether a woman is perimenopausal or post-menopausal and her tolerance for withdrawal bleeding.

Delivery methods include oral tablets, transdermal patches, topical gels and sprays, vaginal rings, vaginal creams, and subcutaneous pellet implants. Each has distinct pharmacokinetic profiles. Transdermal estradiol delivers a steady-state hormone level without hepatic first-pass metabolism, offering advantages for women concerned about clotting risk or those with elevated triglycerides. Vaginal estrogen (cream, ring, or tablet) provides local tissue restoration with minimal systemic absorption and is appropriate for women whose primary complaint is urogenital atrophy. Pellet therapy delivers hormones via subcutaneous insertion and provides sustained release over months, but dosing is less flexible once implanted.

Bioidentical hormones, which are molecularly identical to human estradiol and progesterone, are available in FDA-approved formulations and through compounding pharmacies. FDA-approved bioidentical options include estradiol patches, gels, and micronized progesterone capsules. Compounded formulations allow customized dosing combinations but lack the standardized quality control of commercially manufactured products. The choice between FDA-approved bioidenticals, compounded bioidenticals, and conventional synthetics involves weighing evidence quality, clinician expertise, patient preference, and individualized risk.

HRT is one of the most extensively studied medical interventions in women's health. The Women's Health Initiative (WHI), a large randomized controlled trial initiated in the 1990s, shaped the public narrative for decades. Initial results from the combined estrogen-progestin arm showed increased risks of breast cancer, coronary events, stroke, and venous thromboembolism, leading to widespread discontinuation. Subsequent reanalysis and extended follow-up revealed that the participant population was older (average age 63 at enrollment), and that women who started HRT closer to menopause onset had materially different outcomes, including reduced cardiovascular events and lower all-cause mortality. This finding gave rise to the "timing hypothesis" or "window of opportunity" concept, which multiple observational studies and meta-analyses have since supported.

The estrogen-only arm of the WHI, studied in women who had undergone hysterectomy, showed no increase in breast cancer risk after extended follow-up and demonstrated reduced coronary artery calcification in younger participants. Research comparing transdermal and oral delivery routes, largely from European observational registries, has consistently shown lower thromboembolic risk with transdermal formulations. Studies on bioidentical micronized progesterone suggest a more favorable breast cancer and cardiovascular profile compared to synthetic progestins, though large randomized trials directly comparing the two remain limited. Ongoing research explores HRT's effects on Alzheimer's risk, with observational data suggesting possible neuroprotective effects when initiated during the perimenopausal window, though randomized confirmation is still lacking.

The risks of HRT depend heavily on the type of hormones used, the delivery route, the timing of initiation, and individual patient factors. Combined estrogen-progestin therapy carries a modestly elevated breast cancer risk with prolonged use. Oral estrogen increases the risk of venous thromboembolism and stroke, particularly in women who are obese, smoke, or have clotting predispositions. Women with a history of estrogen-receptor-positive breast cancer, active liver disease, or unexplained vaginal bleeding are generally considered poor candidates for systemic HRT. Side effects can include breast tenderness, bloating, headaches, and irregular bleeding during the initial adjustment period. Any HRT regimen should be supervised by a clinician who monitors labs, reassesses risk annually, and adjusts dosing based on clinical response.